Get started
Work

Supplemental Figure 1 from A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma

Year: 2023
Type: supplementary-materials
Abstract: Supplemental Figure 1. Pharmacodynamic effects of CUDC-101 in tumor, skin and PBMCs.
DOI: 10.1158/1078-0432.22461696.v1
Authors: Thomas J. Galloway, Lori J. Wirth, Alexander D. Colevas, Jill Gilbert, Julie E. Bauman, Nabil F. Saba, David Raben, Ranee Mehra, Anna W. Ma, Ruzanna Atoyan, Jing Wang, Barbara Burtness, Antonio Jimeno
Language: English
Open Access status: gold
OpenAlex ID: W4361920255
Cites:
Cited by:
Related to: 10